Company intelligence / Profile preview

bergauf

Framingham, Massachusetts, United Statesimmerbergauf.com ↗

Ownership: Private
Employees: ~120
Development stage: Other

Overview

Prior to its acquisition, BERG developed an AI-driven platform for drug discovery with a focus on oncology and rare diseases. Its lead program BPM31510 reached Phase 2 trials for glioblastoma multiforme and pancreatic cancer, receiving orphan drug designations. The company also advanced other programs in early-stage development targeting oncology indications.

Therapeutic areas: DermatologyMetabolic DisordersOncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

AstraZenecaBoehringer IngelheimUniversity of Oxford

Beyond the preview

Go deeper on bergauf.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bergauf.

Explore the full profile